A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors

Trial Profile

A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Navicixizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 May 2018.
    • 24 Jan 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top